-
Je něco špatně v tomto záznamu ?
Interactions of 17β-Hydroxysteroid Dehydrogenase Type 10 and Cyclophilin D in Alzheimer's Disease
Z. Kristofikova, T. Springer, E. Gedeonova, A. Hofmannova, J. Ricny, L. Hromadkova, M. Vyhnalek, J. Laczo, T. Nikolai, J. Hort, T. Petrasek, A. Stuchlik, K. Vales, J. Klaschka, J. Homola,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
16-27611A
AZV CR
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2009-08-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- 17-hydroxysteroidní dehydrogenasy mozkomíšní mok metabolismus MeSH
- Alzheimerova nemoc metabolismus MeSH
- amyloidový prekurzorový protein beta genetika MeSH
- kinetika MeSH
- lidé MeSH
- mitochondrie metabolismus MeSH
- mozek metabolismus MeSH
- peptidylprolylisomerasa F metabolismus MeSH
- potkani transgenní MeSH
- potkani Wistar MeSH
- povrchová plasmonová rezonance MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
The nucleus-encoded 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) regulates cyclophilin D (cypD) in the mitochondrial matrix. CypD regulates opening of mitochondrial permeability transition pores. Both mechanisms may be affected by amyloid β peptides accumulated in mitochondria in Alzheimer's disease (AD). In order to clarify changes occurring in brain mitochondria, we evaluated interactions of both mitochondrial proteins in vitro (by surface plasmon resonance biosensor) and detected levels of various complexes of 17β-HSD10 formed in vivo (by sandwich ELISA) in brain mitochondria isolated from the transgenic animal model of AD (homozygous McGill-R-Thy1-APP rats) and in cerebrospinal fluid samples of AD patients. By surface plasmon resonance biosensor, we observed the interaction of 17β-HSD10 and cypD in a direct real-time manner and determined, for the first time, the kinetic parameters of the interaction (ka 2.0 × 105 M1s-1, kd 5.8 × 104 s-1, and KD 3.5 × 10-10 M). In McGill-R-Thy1-APP rats compared to controls, levels of 17β-HSD10-cypD complexes were decreased and those of total amyloid β increased. Moreover, the levels of 17β-HSD10-cypD complexes were decreased in cerebrospinal fluid of individuals with AD (in mild cognitive impairment as well as dementia stages) or with Frontotemporal lobar degeneration (FTLD) compared to cognitively normal controls (the sensitivity of the complexes to AD dementia was 92.9%, that to FTLD 73.8%, the specificity to AD dementia equaled 91.7% in a comparison with the controls but only 26.2% with FTLD). Our results demonstrate the weakened ability of 17β-HSD10 to regulate cypD in the mitochondrial matrix probably via direct effects of amyloid β. Levels of 17β-HSD10-cypD complexes in cerebrospinal fluid seem to be the very sensitive indicator of mitochondrial dysfunction observed in neurodegeneration but unfortunately not specific to AD pathology. We do not recommend it as the new biomarker of AD.
Institute of Physiology of the Czech Academy of Sciences Videnska 1083 142 20 Prague Czech Republic
National Institute of Mental Health Topolova 748 250 67 Klecany Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028330
- 003
- CZ-PrNML
- 005
- 20220221100259.0
- 007
- ta
- 008
- 210105s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11064-020-02970-y $2 doi
- 035 __
- $a (PubMed)31997103
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kristofikova, Zdenka $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic. zdenka.kristofikova@nudz.cz.
- 245 10
- $a Interactions of 17β-Hydroxysteroid Dehydrogenase Type 10 and Cyclophilin D in Alzheimer's Disease / $c Z. Kristofikova, T. Springer, E. Gedeonova, A. Hofmannova, J. Ricny, L. Hromadkova, M. Vyhnalek, J. Laczo, T. Nikolai, J. Hort, T. Petrasek, A. Stuchlik, K. Vales, J. Klaschka, J. Homola,
- 520 9_
- $a The nucleus-encoded 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) regulates cyclophilin D (cypD) in the mitochondrial matrix. CypD regulates opening of mitochondrial permeability transition pores. Both mechanisms may be affected by amyloid β peptides accumulated in mitochondria in Alzheimer's disease (AD). In order to clarify changes occurring in brain mitochondria, we evaluated interactions of both mitochondrial proteins in vitro (by surface plasmon resonance biosensor) and detected levels of various complexes of 17β-HSD10 formed in vivo (by sandwich ELISA) in brain mitochondria isolated from the transgenic animal model of AD (homozygous McGill-R-Thy1-APP rats) and in cerebrospinal fluid samples of AD patients. By surface plasmon resonance biosensor, we observed the interaction of 17β-HSD10 and cypD in a direct real-time manner and determined, for the first time, the kinetic parameters of the interaction (ka 2.0 × 105 M1s-1, kd 5.8 × 104 s-1, and KD 3.5 × 10-10 M). In McGill-R-Thy1-APP rats compared to controls, levels of 17β-HSD10-cypD complexes were decreased and those of total amyloid β increased. Moreover, the levels of 17β-HSD10-cypD complexes were decreased in cerebrospinal fluid of individuals with AD (in mild cognitive impairment as well as dementia stages) or with Frontotemporal lobar degeneration (FTLD) compared to cognitively normal controls (the sensitivity of the complexes to AD dementia was 92.9%, that to FTLD 73.8%, the specificity to AD dementia equaled 91.7% in a comparison with the controls but only 26.2% with FTLD). Our results demonstrate the weakened ability of 17β-HSD10 to regulate cypD in the mitochondrial matrix probably via direct effects of amyloid β. Levels of 17β-HSD10-cypD complexes in cerebrospinal fluid seem to be the very sensitive indicator of mitochondrial dysfunction observed in neurodegeneration but unfortunately not specific to AD pathology. We do not recommend it as the new biomarker of AD.
- 650 _2
- $a 17-hydroxysteroidní dehydrogenasy $x mozkomíšní mok $x metabolismus $7 D015067
- 650 _2
- $a Alzheimerova nemoc $x metabolismus $7 D000544
- 650 _2
- $a amyloidový prekurzorový protein beta $x genetika $7 D016564
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a mozek $x metabolismus $7 D001921
- 650 _2
- $a peptidylprolylisomerasa F $x metabolismus $7 D000081406
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mitochondrie $x metabolismus $7 D008928
- 650 _2
- $a potkani transgenní $7 D055647
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a povrchová plasmonová rezonance $7 D020349
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Springer, Tomas $u Institute of Photonics and Electronics of the Czech Academy of Sciences, Chaberska 57, 182 51, Prague, Czech Republic.
- 700 1_
- $a Hemmerová, Erika, $u Institute of Photonics and Electronics of the Czech Academy of Sciences, Chaberska 57, 182 51, Prague, Czech Republic. $d 1991- $7 xx0269692
- 700 1_
- $a Hofmannova, Adéla $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic.
- 700 1_
- $a Ricny, Jan $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic.
- 700 1_
- $a Hromádková, Lenka, $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic. $d 1987- $7 xx0268843
- 700 1_
- $a Vyhnalek, Martin $u Department of Neurology, Memory Disorders Clinic, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V uvalu 84, 150 06, Prague 5, Czech Republic.
- 700 1_
- $a Laczo, Jan $u Department of Neurology, Memory Disorders Clinic, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V uvalu 84, 150 06, Prague 5, Czech Republic.
- 700 1_
- $a Nikolai, Tomas $u Department of Neurology, Memory Disorders Clinic, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V uvalu 84, 150 06, Prague 5, Czech Republic.
- 700 1_
- $a Hort, Jakub $u Department of Neurology, Memory Disorders Clinic, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V uvalu 84, 150 06, Prague 5, Czech Republic.
- 700 1_
- $a Petrasek, Tomas $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic. Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic.
- 700 1_
- $a Stuchlik, Ales $u Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic.
- 700 1_
- $a Vales, Karel $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic.
- 700 1_
- $a Klaschka, Jan $u Institute of Computer Science, Czech Academy of Sciences, Pod vodarenskou vezi 271/2, 182 07, Prague, Czech Republic.
- 700 1_
- $a Homola, Jiri $u Institute of Photonics and Electronics of the Czech Academy of Sciences, Chaberska 57, 182 51, Prague, Czech Republic.
- 773 0_
- $w MED00003484 $t Neurochemical research $x 1573-6903 $g Roč. 45, č. 4 (2020), s. 915-927
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31997103 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20220221100257 $b ABA008
- 999 __
- $a ok $b bmc $g 1608665 $s 1119510
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 45 $c 4 $d 915-927 $e 20200129 $i 1573-6903 $m Neurochemical research $n Neurochem Res $x MED00003484
- GRA __
- $a 16-27611A $p AZV CR
- LZP __
- $a Pubmed-20210105
